Document XzdQ0qdvGDMEJrE9dVBOa8NR

CHEMICAL MANUFACTURERS ASSOCIATION Vinyl Chloride Health Committee Record of Meeting DATE: TIME: PLACE: Tuesday, November 26,1996 9:00 a.m. to 3:00 p.m. CMA Offices Arlington, VA List of Attendees: Jim Barter (p/t) Mark Gruenwald David Pirn Jonathan Ramlow JimKnaak Dave Penney Jay Strange PPG Industries, Inc. Borden Chemicals & Plastics, Inc. Formosa Plastics Corp. The Dow Chemical Company Occidental Chemical Corp. CONDEA Vista Chemical Company Georgia Gulf Corporation Caffey Norman Patton Boggs, LLP Cynthia Barrett Robert Venezia CMA CMA 1.0 Approval of July 31,1996 Record of Conference Call Changes were made to Item #2.0 in the Record. Robert Venezia will make the changes and send the revised Record to the Committee. 2.0 Update on the Developmental, Reproductive and Mechanistic Research Studies 2.1 Memorandum of Understanding with the Agency for Toxic Substances and Disease Registry (ATSDR) Dr. VawriajjJUB-LIII up* ill..... iho pf ^4DTT recommended that the Committeeproyide-ATSKCwithapjp^ of the protocols fonthe sateUite^bMtieCTdnNormanjjso-eecSmmafided revising t^jiahvefaBlesdatesjnJhemaurSfuSy plan. Eh-. Venezia and r-<iav<11a* <nwi<y<Fivki v* graining those chaagegTj CMA 119469 Vinyl Chloride Health Committee Record of Meeting -11 /26/96 Page 2 J fee; ^ ' l' i"L 2.2 InfaitadanXiR ULmiffiliu-.--1--------I-- Jim Knaak gave an update of study activities at Huntingdon. Dr. Knaak was interested in the results of the preliminary analytical work on the test material and exposure chambers. Based upon Dr. Knaak's appraisal of Huntingdon's analytical data, the Committee agreed that verification of the chamber concentrations using a gas chromatograph-infrared comparison method will be performed once a week during the first month of the study and twice a month thereafter. However. Dr. Knaak will continue to monitor the results of the analytical work to determine if adjustments in the proposed verification schedule will be necessary. The Committee also discussed a replacement for Bill Breslin as a technical consultant assigned to the studies. The Committee agreed that Dr. Knaak would replace Dr. Breslin. Dave Penney agreed to serve as a consultant to the Committee for the studies. The Committee approved funds for Drs. Knaak's and Penney's travel expenses to visit Huntingdon laboratories at critical points during the study. Dr. Knaak also reported that study animals will be ordered during the week of December 23,1996 and that the chambering should begin during the second week in January. Dr. Venezia will request a calendar of critical study dates from Ray Schroeder of Huntingdon Life Sciences. S.tll.U 3fJL 2.3 tmreemity of North Carolina James Swenberg. Dr. Venezia reported that Jim Swenberg and Mr. Schroeder are collaborating to develop a final protocol for the satellite studies. Dr. Swenberg determined that the number of animals needed for the studies could be reduced without undermining validity and that the studies need not be held strictly to GLP standards. Therefore, the total coosstt orf tmhe , , studies is significantly loweip v-uJl tU , l%c--M q. r __ LW MM "f i lJL /f 2.4 13Cj Vinyl Chloride Synthesis ^) /\ / L 4i Dr. Venezia reported that Huntingdon received the l3C2-VC ii tL 3.0 Update on the International Life Sciences Institute Genotoxicity Project iM^U The Committee reviewed the status report on the Project provided by Gino Scarancrof ILSI. Dr. Venezia explained that the Committee and EPA are among several sponsors of the Project. Dr. Venezia will proposes: meeting between ILSI and the sponsors of the project to ask more in-depth questions about the nature of the project and its intended uses. CMA119470 Vinyl Chloride Health Committee Record of Meeting -11126/96 Page 3 4.0 Update on EPA's IRIS Pilot Project The Committee agreed to wait until the external review phase of the IRIS Pilot Project before commenting to EPA on the IRIS entry for vinyl chloride. 5.0 Update on the University of Louisville Brain Cancer Study Jonathan Ramlow provided background on the study protocol and Carlo Tamburro's progress. Jim Barter identified pagination errors in the final study protocol. Dr. Venezia will correct the errors with Dr. Tamburro. Dr. Venezia also will arrange a conference call among Drs. Tamburro. Barter and Ramlow to discuss progress on the study. 6.0 Update on the Vinyl Chloride Cohort Study with Applied Epidemiology Inc. Ken Mundt was conferenced into the meeting to provide an update. Dr. Mundt reported that he requires additional data collection assistance from Occidental Chemical Corp. and Formosa Plastics Corp. Dr. Mundt will contact those Committee members directly with details of the information he still needs. Dr. Mundt reported that he had not yet heard from Carlo Tamburro. Dr. Venezia will send to Ken Mundt the final protocol from Dr. Tamburro's study. 7.0 Discussion of National Institutes of Health Activities with Vinyl Chloride Dr. Venezia verified that NIH is not working on vinyl chloride issues. 8.0 Update on the Agreement with ENSR Dr. Venezia reported that this issue has been settled^ & ^ 9.0 Update on ATSDR Activities ^ P>J'j t*. 9.1 Status of Comments on the Toxicological Profilefor Vinyf Chloride 'w/T The Committee will send corrections to the section ori nHfiufacture, use and disposal to Dr. Venezia. Dr. Venezia and qA/fetyfoorman will draft a Xletter to ATSDR recommending that ATSDR incorporate these corrections A 0'S & use published statistics on the name plate capacitiesjof vinyl chloride 9.2 Status of Activity on the Minimal Risk Level for Vinyl Chloride Dr. Knaak reported that HSIA intends to hold a computational workshop on the MRLs in conjunction with ATSDR. Dr. Knaak will report on the workshop at a later Committee meeting. CMA 119471 Vinyl Chloride Health Committee Record of Meeting * 11/26/96 I MtU. I--,-} \ oviJ 10.0 Status of a Petition to Raise the EPA Reportable Quantity (RQ) for Vinyl \ t'/1 A '' - <_> Chloride \ ft fc. K>A Mr. Norman described an unsuccessful t- chloride to 10 poundis. MMrr.JNjoorman will provide more background on the trrtinf--1 rrirnrii fnr mi linn FHi Pr Yrnrrh in'll contact Frank Borelli of The VIinvl Institute to determine ^intended course of action on this iasua ;t> ** 11.0 Discussion of OSHA Clarification of Medical Surveillance Provision of Vinyl Chloride Standard The Committee discussed the possible relevance of this standard to the ATSDR Medical Management Guidelines. 12,0 Discussion of EPA's Air Toxic Program sdt*J ^ / ^ Ailt.iUjJ tl ** t*`n ifc'rtl')'] Mr. Norman provided background on itus ttsua. Mr. Norman will provide the Committee with an update on EPA's activities and additional background on this issue. Mr. Norman will write a letter to EPA requesting that the Committee be included on fteir Hstnf interested stakeholders. 13.0 Discussion of the Association of Plastics Manufacturers in Europe Registry of Angiosarcoma Cases Dr. Venezia will determine if this registry is the world registry formerly maintained in England. Dr. Venezia also will provide a list of world manufacturers of vinyl chloride. Committee members decided JVtio action will be taken^ 14.0 Discussion of the ACGIH Initiative to Lower the Threshold Limit Value for Vinyl Chloride k Dr. Venezia will prepare a letter to William Waddell of ACGIH offerine to .. present to his Committee information relevant to the TLV for vinyl chloride. tbKxlA Discussion of CalEPA's Developmental and Reproductive Identification Committee Priority Listing of Vinyl Chloride Dr. Venezia will contact a member of CalEPA's Developmental and Reproductive Toxicant Identification Committee to ensure that CalEPA received the Committee's comments. U IAa i Kcc-nt J i. /y /-~ it tlu J St J, CMA119472 Vinyl Chloride Health Committee Record of Meeting -11/26/96 PageS u.fc U, *i.l a"L' ^ ^ v,,,,n . an ----, ,_____ --------------- ,.* /V * 16.0 Discussion of EPA's Request for Company sponsorship of Vinyl Chloride in s ^1 " ` . the Organization for Economic Cooperation and Development's Screening v " Information Datasets Program. IKsJU Hr.MvJ *>' N"*~ .( , *'n h"'"" * r`v' >, a nhT- The Committee agreed lu wdil milll allei the January 8,1997IIAPo meeting withCharlie Auor at HSIA te make a decision regarding vinyl chloride in the OECD -SIDE Program. ^ 1 Dr. Venezia will obtain the existing SIARS and HEDSETS on vinvl chloride and ethylene dichloride and distribute them to the Committee. 17.0 Discussion of the Draft Study Report of the Cost Impact of Canadian New Substances Notification Regulations Dr. Venezia will discuss this issue with the CMA International Affairs Department ^determine if they have addressed this issue. Jtf,. ^' jyv\a i 18.0 Discussion of the 1997 Budget ' " The budget for 1997 was approved unanimously. cUL^.Ji ('l/'rf, fj ---- J 19.0 Schedule Next Conference Call or Meeting The next conference call will be on Thursday, January 16,1997 at 2:00 p.m. Subject to Approval Robert A. Venezia, Dr.P.H. Manager Vinyl Chloride Health Committee CMA 119473